Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki‐Ito, Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui
Topics & Concepts
MedicineInternal medicineHazard ratioMetastatic Urothelial CarcinomaSalvage therapyPembrolizumabConfidence intervalDocetaxelGemcitabineProportional hazards modelUnivariate analysisOncologySurgical oncologyRetrospective cohort studyMultivariate analysisGastroenterologyChemotherapyCancerImmunotherapyBladder cancerUrothelial carcinomaBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersRenal cell carcinoma treatment